Provention Bio Inc. was the first company to reveal that one of its clinical trials will be halted to prevent infection of study participants with SARS-CoV-2, the virus that causes COVID-19, but at least two other biopharmaceutical firms have delayed initiation of upcoming trials and more studies will be impacted as coronavirus case numbers rise globally.
Oldwick, NJ-based Provention announced on 16 March that it would stop enrolling new patients but continue to treat already enrolled children and adolescents between the ages of 8 and 17 in the Phase III PROTECT study of PRV-301 (teplizumab) in the treatment of newly diagnosed type 1 diabetes
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?